Introduction This guidance support trusts and community providers to enable front line staff to fulfil their legal requirements around the Mental Capacity Act (MCA) 2005; specifically when supporting ...

This poster presentation provides the investigators with the opportunity to discuss the detailed results on VCN-01 safety and long-term efficacy in this population with a broader clinical oncology ...

BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical ...

Press Release Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on ...

(“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in ...

Onsite Parexel experts include recently appointed Chief Medical Officer and veteran oncologist Dr. Charlotte Moser, licensed medical oncologist and Global Therapeutic Area Head, Oncology, Dr. Gwyn ...

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is ...

LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, with desirable PK/PD profile and no impact of food on the pharmacokinetics. The maximum tolerated ...

The discussion will follow Dr. Theodore DeWeese's* oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The call will also feature insights from leading prostate ...